Further references
From Cancer Guidelines Wiki
Further references
Further references have been brought to the attention of the Working Party that do not fall within the criteria of reference selection.
These may prove of interest to readers of these Guidelines:
- Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, et al. 'Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 2004 Sep 1;60(1):15-23 [Available at http://www.ncbi.nlm.nih.gov/pubmed/15337535]
- D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 2004 Aug 18;292(7):821-7 [Available at http://www.ncbi.nlm.nih.gov/pubmed/15315996]
- Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 2001 Aug 1;50(5):1243-52 [Available at http://www.ncbi.nlm.nih.gov/pubmed/11483335]
- Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Trans-Tasman Radiation Oncology Group, Lancet Oncol 2005 Nov;6(11):841-50 [Available at http://www.ncbi.nlm.nih.gov/pubmed/16257791]
- Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial Lancet Oncol 2008 Nov;9(11):1058-68 [Available at http://www.ncbi.nlm.nih.gov/pubmed/18929505]
- Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 2005 Apr 1;61(5):1285-90 [Available at http://www.ncbi.nlm.nih.gov/pubmed/15817329]
- Bolla M, De Reijke TM, Van Tienhoven G, Van den Bergh ACM, Oddens J, Poortmans PMP et al. Duration of androgen supression in the treatment of prostate cancer. N Engl J Med. 2009 Jun;360(24):2516-27 [Available at http://www.ncbi.nlm.nih.gov/pubmed/19516032}
- D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, et al. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate Cancer 2007 May 15;109(10):2004-10 [Available at http://www.ncbi.nlm.nih.gov/pubmed/17397033]
- Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 2007 Jun;8(6):475-87 [Available at http://www.ncbi.nlm.nih.gov/pubmed/17482880]